Xeljanz is expected to go generic after its primary patent expires on July 26, 2025 [1]. This date pertains to the U.S. patent for the drug [1].
When does Xeljanz's market exclusivity end?
Market exclusivity for Xeljanz in the United States is tied to its patent protection. The key patent for Xeljanz, U.S. Patent No. 9,724,507, is set to expire in July 2025 [1]. After this date, generic versions of Xeljanz may become available.
Are there any other patents for Xeljanz?
While the 2025 date marks the expiry of a primary patent, pharmaceutical companies often hold multiple patents covering different aspects of a drug, such as formulation, manufacturing processes, or specific uses. These additional patents can sometimes extend market exclusivity beyond the primary patent's expiration date. For detailed information on all relevant patents, DrugPatentWatch.com is a valuable resource [1].
Can generic versions be launched before the patent expires?
Generic manufacturers may challenge existing patents to attempt an earlier market entry. If a patent is successfully invalidated or found to be non-infringed, a generic version could be approved and launched before the original patent's expiration. Conversely, if a patent is upheld, the generic launch would be delayed until after its expiry.
What is the active ingredient in Xeljanz?
The active ingredient in Xeljanz is tofacitinib citrate [2]. Generic versions of the drug will contain the same active ingredient.
How does Xeljanz work?
Xeljanz is a Janus kinase (JAK) inhibitor. It works by blocking the activity of certain enzymes in the body that are involved in inflammation [2]. This mechanism helps to reduce the symptoms of autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Who manufactures Xeljanz?
Xeljanz is manufactured by Pfizer Inc. [2].
What is the expected impact of generic Xeljanz on pricing?
The introduction of generic alternatives typically leads to a significant reduction in drug prices. Once generic tofacitinib citrate becomes available, it is expected that the cost for patients and healthcare systems will decrease considerably.
What are the alternatives to Xeljanz?
Patients and physicians consider various treatment options for autoimmune diseases. Alternatives to Xeljanz may include other JAK inhibitors, or different classes of medications such as TNF inhibitors, DMARDs, and corticosteroids, depending on the specific condition being treated and the patient's individual needs and response to therapy.
What conditions is Xeljanz approved to treat?
Xeljanz is approved for the treatment of adults with:
* Moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate [2].
* Active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other treatment for psoriatic arthritis [2].
* Ulcerative colitis who have had an inadequate response or intolerance to conventional treatment [2].
Sources:
[1] DrugPatentWatch.com. (n.d.). Xeljanz Patent Expirations. Retrieved from https://www.drugpatentwatch.com/
[2] Pfizer Inc. (n.d.). Xeljanz Prescribing Information.